Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | PNP | P00491 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598599 | 0.80 | ALDH1A1 (0.55) | AHRALDH1A1HSD17B10CCR8 | |
| SCHEMBL2698875 | 0.79 | DYRK1A (0.43) | AHRALDH1A1HSD17B10KDM4EPNP | |
| SCHEMBL2211390 | 0.75 | MAPK1 (0.45) | ALDH1A1KDM4E | |
| SCHEMBL15058364 | 0.73 | AHR (0.45) | AHRALDH1A1GPR84SYKKDM4E | |
| SCHEMBL5598446 | 0.72 | HSD17B10 (0.43) | ALDH1A1HSD17B10GPR84KDM4E | |
| SCHEMBL26958356 | 0.71 | AHR (0.40) | AHRGPR84SYKCHEK1PARP1 | |
| SCHEMBL669933 | 0.71 | AXL (0.42) | ALDH1A1HSD17B10CCR8PARP1 | |
| SCHEMBL29953488 | 0.70 | CCNT1 (0.38) | ALDH1A1KDM4E | |
| SCHEMBL21988117 | 0.69 | TDP1 (0.37) | ALDH1A1KDM4E | |
| SCHEMBL291660 | 0.68 | PSMD14 (0.61) | ALDH1A1KDM4EDAOGRM4CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231663-B1 | 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS | AMGEN INC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3170824-A1 | 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS | Amgen, Inc (US) | 2017-05-24 | — | — | EP | disclosed |
| CN-106083899-A | Condensed heterocyclic derivates and using method | 安姆根有限公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-102007125-B | fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2016-05-25 | — | — | CN | disclosed |
| US-9066954-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-8524900-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8217177-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8198448-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2231663-A2 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AS C-MET INHIBITORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009091374-A2 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | AHR 117/4885ALDH1A1 156/4885HSD17B10 876/4885 |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | AHR 117/4885ALDH1A1 156/4885HSD17B10 876/4885 |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | AHR 117/4885ALDH1A1 156/4885HSD17B10 876/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | AHR 117/4885ALDH1A1 156/4885HSD17B10 876/4885 |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | AHR 117/4885ALDH1A1 156/4885HSD17B10 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.